JPMorgan Chase & Co. Acquires 227,864 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX)

JPMorgan Chase & Co. increased its holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX) by 512.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 272,328 shares of the company’s stock after buying an additional 227,864 shares during the period. JPMorgan Chase & Co. owned 0.20% of Compass Therapeutics worth $395,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Intech Investment Management LLC lifted its position in shares of Compass Therapeutics by 218.7% during the fourth quarter. Intech Investment Management LLC now owns 51,924 shares of the company’s stock worth $75,000 after acquiring an additional 35,632 shares in the last quarter. Sequoia Financial Advisors LLC bought a new stake in shares of Compass Therapeutics during the 4th quarter valued at $45,000. Independent Advisor Alliance purchased a new stake in Compass Therapeutics during the 4th quarter worth about $26,000. Bank of New York Mellon Corp lifted its holdings in Compass Therapeutics by 2.6% during the 4th quarter. Bank of New York Mellon Corp now owns 237,975 shares of the company’s stock worth $345,000 after purchasing an additional 6,041 shares in the last quarter. Finally, Rhumbline Advisers boosted its stake in Compass Therapeutics by 3.1% in the 4th quarter. Rhumbline Advisers now owns 129,116 shares of the company’s stock worth $187,000 after purchasing an additional 3,822 shares during the period. 68.43% of the stock is owned by institutional investors.

Compass Therapeutics Stock Performance

Compass Therapeutics stock opened at $1.82 on Friday. Compass Therapeutics, Inc. has a fifty-two week low of $0.77 and a fifty-two week high of $4.08. The stock has a market cap of $251.68 million, a P/E ratio of -4.92 and a beta of 1.40. The firm’s fifty day moving average price is $2.12 and its 200-day moving average price is $2.10.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). On average, analysts predict that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current year.

Insider Activity at Compass Therapeutics

In related news, Director Carl L. Gordon sold 3,571,428 shares of the stock in a transaction on Wednesday, April 9th. The shares were sold at an average price of $1.59, for a total transaction of $5,678,570.52. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Jonathan Anderman purchased 20,000 shares of the stock in a transaction on Monday, April 7th. The stock was acquired at an average cost of $1.54 per share, with a total value of $30,800.00. Following the completion of the purchase, the insider now directly owns 21,000 shares of the company’s stock, valued at $32,340. The trade was a 2,000.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 28.50% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on CMPX shares. Guggenheim reiterated a “buy” rating on shares of Compass Therapeutics in a research report on Tuesday, April 22nd. Piper Sandler initiated coverage on shares of Compass Therapeutics in a report on Wednesday, February 19th. They set an “overweight” rating and a $12.00 target price on the stock. Wedbush reissued an “outperform” rating and issued a $8.00 price target on shares of Compass Therapeutics in a report on Tuesday, April 1st. Leerink Partnrs raised shares of Compass Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, April 1st. Finally, Leerink Partners raised Compass Therapeutics from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $4.00 to $6.00 in a research note on Wednesday, April 2nd. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $13.38.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.